#transdermal patches are used for

[chicago-geniza]

[Guy who scored in the 99th percentile during ADHD testing and has had lifelong problems with drugs voice] Why do people not use transdermal nicotine patches as a regular way to boost their energy or clear their brain fog when it's more effective in the longue duree, cheaper to buy in bulk, and less damaging to the digestive tract than caffeinated beverages. You can buy them over the counter and they don't harm the lungs like inhaling cigarette smoke, plus they last for 24 hours--

[starlit-writer]

omegaverse au masterpost

hello lovelies! as i get more into posting about omegaverse, i wanted to put out an explanatory post about what a/b/o dynamics and attributes look like in my au. so, without further ado, i present to you, starlit's guide to the omegaverse <3

DESIGNATIONS Alphas, betas, and omegas are considered “secondary” genders. “Primary” genders (male, female, gender nonconforming, transgender ftm/mtf, etc.) all still exist, and are still the first, most noticeable gender presentation. A person’s designation (their secondary gender) is typically hidden, especially if they are an omega.

In the society of my AU, alphas are seen as the “top dogs”. They are typically the ones who are in power, looked to for decision making, expected to be the ones working and fighting and staking claims. Betas are mostly ignored, however, that allows them to still find success, as they are not usually taking the brunt of legislature about what they can or cannot do. Omegas are typically seen as the most oppressed designation. Many years ago, there were many legislations that dictate that omegas should be mated, and restricted to the home to care for the house, pups, their alpha and their pack. However, there was a major push against these laws a few years back, which saw many of these laws overturned, but the societal impact of these laws is still holding strong. While there are many people who see these laws and their impact as archaic, society is slow to change, so most omegas go to great lengths to hide their designation to allow them to avoid discrimination, to find work and their own success outside of the home.

SCENTS “Scent” glands are glands that exist on both omegas and alphas with the express purpose of releasing their pheromones. Betas (typically) do not possess these scent glands. However, a beta might have one or two “redundant” scent glands, but the scent they give off is very, very minimal, with no pheromones inside of the scent, and is nowhere near as powerful as an alpha or omegas scent. However, if an omega goes into heat without their alpha around, a pack beta who has these redundant scent glands would be able to soothe the omega slightly, enough to prevent heat sickness. For alphas and omegas, there are six scent glands, located in:

Under the jaw, right in front of the ears

In the juncture of the neck and shoulder (over the trapezius muscle)

The inner wrists

Behind the knees

Scent blockers are very common, as they dampen a person’s natural scent. A person’s scent displays strong emotions through the pheromones, which can affect others (i.e, an angry alpha will put everyone on edge). Due to this, alphas and omegas mainly use scent blockers out of politeness - it's seen as rude to flaunt around your natural scent without dampening as an adult, due to the effect that these pheromones can have on others. However, for omegas especially, scent blockers give an extra layer of protection against unwanted mating and discrimination. Since omegas are typically the first receiver of the mating bite, which is placed on the scent gland that is found in the juncture of the neck and shoulder, they will typically add in an extra layer of protection with scent blocker patches.

Scent blockers come in three versions: sprays, roll-on (like stick deodorant), and patches. Sprays are the weakest form of scent blockers, roll-ons range in power (think of the difference between deodorant and deodorant+antiperspirant), while patches are the strongest form. Roll-on and patch scent blockers can also come with a transdermal form of heat/rut suppressants for omegas and alphas inside of them, much like birth control patches. However, very strong, typically negative, emotions will still come through even the strongest of patches, like the grief of an omega losing their alpha, or the rage of an alpha when their omega is in danger.

There are really only two times that it is totally acceptable for scent blockers to not be used. The first is during the “newlymate” time, where the pheromones of the alpha and omega must be completely unmasked in order for the mating bond to fully form. The other is for pups. Pups cannot use scent blockers until after they fully complete puberty, as blocking an immature scent gland can permanently alter or even destroy the forming gland and its development.

INNER ALPHA/INNER OMEGA An "inner alpha" or "inner omega" is seen as the more instinctual, less rational side of a person. Most times imagined as an internal, separate version of a person that is completely controlled by their emotions and designation-based instincts. Betas do not typically have an “inner beta”, as they do not have the same instincts, pheromones, or evolutionary changes as an alpha or an omega.

COURTING When there are two people who want to initiate a bond, there is typically a courting process. First, it typically starts with the alpha presenting the omega with gifts. These gifts start as small offerings: trinkets that the omega might like, food, helping with tasks for the omega, etc. If these offerings are accepted, the second part of the courting process starts, which looks a lot like dating. After a few months of dating, the third part of the courting takes place, where the alpha and the omega offer something that has their scent on it, typically an article of clothing. If those are accepted, the fourth stage of the courting takes place, which is known as the courting chase.

In this stage, an omega initiates the chase. Running away from the alpha is the start of the chase. This is done without scent blockers, to allow the alpha to follow the omega’s scent trail. If the chase is accepted, the alpha follows suit. This chase allows the more primal instincts of the omega and alpha to come to the surface. Once the omega is caught, this is typically when the mating bond is performed. This will also kickstart the heat/rut cycle of the two individuals, which helps to cement the bond further.

MATING/BONDING Mating and bonding are two terms that can be used interchangeably. As explained earlier, the mating bite is placed on the gland in the juncture between the neck and shoulder with the longer, sharper canines of an omega or alpha. Betas can bite, but their canines are not long enough to properly puncture the gland to create a bond. However, if an unmated omega is going through heat or an unmated alpha is going through a rut, a beta can help them through without fear of an accidental mating or pregnancy (as long as proper precautions are taken such as birth control and condoms) to prevent rut/heat sickness. A beta’s bite cannot form a mating bond, but it can ease the discomfort.

A mating bond is formed when an alpha and omega perform a mating bite on each other. If only one person performs the mating bite, the bond is temporary, and will fade without a reciprocal bite. When a mating bond is in place, the emotions of the mates are able to be felt by the other, and the heat/rut cycles become synced between the mates.

When a mating bond is fresh, the mates should not be separated, as emotions and instincts are incredibly high due to the bond settling. If separated, the mates can become agitated, and at worst, incredibly violent. Due to this, “newlymates” get a special leave from work called “newlymate” or “newlybond” leave.

Bond sickness is another important aspect (risk) of mating. If one of the mates is neglected, their needs not met, the mating bond will start to strain. The beginning stages look a lot like a common cold or flu, but if the neglect continues, the symptoms worsen. As the bond continues to fray, the sickness gets worse, leading to psychopathy, coma, and even death.

PACK DYNAMICS Packs are units of individuals that can be formed with any and all designations. These are deep bonds, but they are different from mating bonds. Packs are intrinsically linked to one another, but it's more of a heightened awareness of each other rather than the concrete linkage of a mating bond. There may be mated pairs within a pack, but a pack is more of a family-type unit. This can be an actual biological family, or it can be a found family. Pack members all take care of each other, and it makes it much easier to move through the world as a pack. Found family packs are very common with younger people, and are typically very knit, going so far as helping each other through heats/ruts. If there is an unmated omega/alpha in the group, other unmated individuals would be the first choice to help them through their heat/rut, as they have the familiar pack scent associated with them, which helps prevent heat/rut sickness.

SOULMATES On occasion, more rare than not, an alpha and omega are soulmates. This typically happens when their inner omega and inner alpha decide that their pheromones are biologically compatible, and it drives the two individuals together. This is what every omega and alpha hopes for, is to find their soulmate, as these are seen as the strongest, most stable, and longest-lasting relationships that are the most fulfilling.

[writers-potion]

i was wondering if you could give some points and tips on writing about a character who is suffering from DRUG ABUSE

Writing A Drug Addict Character

Know Your Drugs

Was the drug invented? A scene using insulin set in 1820 is problematic since this treatment wasn’t discovered until the 1900s. Fentanyl shouldn’t be used in a 1930s scene since it wasn’t available for use until the 1960s—opium or morphine would be more accurate choices.

Was the method invented? Since insulin must be given as a shot, that scene is even less authentic as the hypodermic needle wasn’t invented until the mid-1800s. Older historical fiction could involve the use of poultices and mustard packs, while skin drug patches (transdermal patches) are only appropriate in more modern scenes.

The most common drugs abused by gangs are: Marijuana, Methamphetamine, Heroin, Cocaine

Or, it can be prescription drugs

Although many medications can be abused, the following three classes are most commonly abused:

Opioids—usually prescribed to treat pain;

Central nervous system (CNS) depressants—used to treat anxiety and sleep disorders; and

Stimulants—most often prescribed to treat attention deficit hyperactivity disorder (ADHD). (common example? caffeine)

Write In Stages

Stage 1: First Use

Some people use a substance for the first time out of curiosity, while others use substances due to peer pressure. People may also be prescribed medication, such as opioids, by their doctor. Individuals may view their first use as a one-time occurrence, but this opens the door for future use. Some people try a substance one time and never use it again. 

You character will feel:

Angry and/or desperate

Miserable

Lonely

Trying to run away from a certain problem

Persuaded into doing drug

Guilty

Stage 2: Regular Use

If a person uses a substance and enjoys how it makes them feel or believes it will improve their life, they may start to use the substance regularly. They may use drugs or drink alcohol on the weekends while at parties or hanging out with friends. Occasional use may become a regular occurrence. It might become a part of a person’s routine.

Your character:

Will start getting in careless activities while doing drugs

Will probably be violent

Won’t think he has any issue whatsoever and shrug it off

Start associating themselves with harder drug users

Have a false sense of security that they’re able to quit whenever they want.

Stage 3: Risky Use

The next stage after regular use is risky use. A person will continue to use a substance despite the physical, mental, legal or social consequences. Their use likely started as a way to escape or have fun with peers but has now taken priority over other aspects of their life.

Your Character will feel:

uncomfortable around family members/friends who start to notice

Exhibit more reckless behavior

Driving under influence, stealing money to finance substance use, etc.

Underperforming at work or school

Experience tension in personal relationships

Stage 4: Dependence

The next stage is a physical, mental and emotional reliance on the substance. The individual is no longer using the substance for medical or recreational purposes. When a person doesn’t use the substance, their body will exhibit withdrawal symptoms, such as tremors, headaches, nausea, anxiety and muscle cramps.

Your Chracter Will:

Develop a sort of rountine/typical place where they abuse

Believe that the substance is essential for survival

Use substance even when it's unnecessary

Stage 5: Substance Use Disorder

While some people use dependency and substance use disorder interchangeably, they’re very different. Once a person develops a substance use disorder, substance misuse becomes a compulsion rather than a conscious choice. They’ll also experience severe physical and mental side effects, depending on the substance they’re using.

Your Character:

Has noe developed a chronic disease with the risk of relapse

Is now incapable of quitting on their own

Feel like life is impossible to deal with without the substance.

Lose their job, fail out of school, become isolated from friends and family or give up their passions or hobbies.

Research the Trends

Medical knowledge changes over time and with it the drugs prescribed. This then impacts the type of prescription drugs available on the streets.

late 1800s: chloral hydrate used for anxiety and insomnia > bromides > 1920s: barbiturates, barbital > benzodiazepines ("benzos") > early 2000s: opiod drugs > opiod drug bans led to growth of black markets: ilicit fentanyl > and so on...

Different countries/locations will have varying trends of drug abuse (depending on laws, availability, costs, etc.)

Research the Slag

look for "[drug name] trip report" on YouTube, etc. to get first-hand accounts of how drug addicts behave.

The main focus should always be to use the words your characters would use in ways that suit the world you have created.

The slang for certain drugs is a difficult vocabulary to maintain as it is ever-changing and varies based on country, region, town, even by streets. Some writers use what they know or have heard locally, others invent their own.

Resources

FDA (Food and Drug Administration) and DEA online databases and drug resources

Social networking groups focusing on related specialty writing topics, such as trauma or emergency medicine

Newspaper articles and medical journals are great places to find real cases.

The US national poison center 

Helpful Vocab:

Addled - sense of confusion + complete lack of mental awareness

Crazed - emotional anguish experienced by the addict

Desperate

Despondent

Erratic

Fidgety

Hopeless

Impressionable

Struggling

[religion-is-a-mental-illness]

By: Colin Wright

Published: Jun 25, 2025

In recent years, administering estrogen to males who identify as transgender women has become increasingly common, including among adolescents. Often paired with testosterone blockers, this treatment is marketed as part of “gender-affirming care”—a term used to describe medical interventions intended to “align” a person’s body with his or her “gender identity.” But as more young people pursue medical transition in the absence of long-term studies, concerns about safety, efficacy, and informed consent have grown more urgent.

A recent review article in Discover Mental Health, entitled “Emerging and accumulating safety signals for the use of estrogen among transgender women,” and authored by Lauren Schwartz and colleagues, tries to fill that gap. It compiles studies, case reports, and group data to spotlight a range of serious health risks—some well-known, others emerging—associated with long-term estrogen use in males.

Understanding the risks of cross-sex hormone therapy is important not only for clinicians and patients but also for policymakers, parents, and the broader public. Medicalized gender transition for minors is becoming increasingly common, even as major questions about long-term outcomes remain unanswered. That disconnect makes the work of Schwartz et al. especially important.

One of the best-known risks associated with estrogen use in males is infertility. In their new review, Schwartz et al. note that while some patients retain limited sperm production, many do not—and they exhibit “testicular atrophy, hyalinization, and fibrosis,” meaning shrinkage, scarring, and tissue changes that may signal elevated cancer risk. A recent systematic review cited in the paper found that taking estrogen alongside testosterone blockers was linked to “higher proportions of sperm abnormalities . . . or azoospermia” (complete loss of sperm). Some of these effects may be reversible, but others are not. Tissue studies following orchiectomies (surgical removal of the testes) show widespread damage.

Cardiovascular complications are another well-documented concern. Multiple studies cited in the review report higher rates of dangerous blood clots—known as venous thromboembolism (VTE)—and strokes among trans-identifying males taking estrogen. One meta-analysis found VTE incidence more than twice as high as in non-trans-identifying males. A cohort study showed that after two years of estrogen use, the risk of VTE was over five times higher; after six years, the risk of ischemic stroke was nearly ten times higher than in non-trans-identifying males. While some research suggests that transdermal estrogen (patches or creams) may carry a lower clotting risk than oral forms (pills), all delivery methods appear to elevate cardiovascular risk.

The paper also highlights potential cognitive risks, including memory loss and early-onset impairment. While short-term studies haven’t consistently shown problems, longer-term research on older transgender-identifying males taking hormones has found poorer performance on tasks involving memory and processing speed. In postmenopausal women, estrogen use has already been linked to a doubled relative risk of dementia—an effect that appears to extend to trans-identifying males. Survey data likewise show that trans- and nonbinary-identifying adults over 45 report more cognitive difficulties than their non-trans-identifying peers.

Perhaps the most alarming finding cited in the paper is the increased risk of early death. Schwartz and colleagues reference a Dutch cohort study of patients treated at a major gender identity clinic, which found that “the overall mortality risk of [trans-identifying men] . . . was higher compared to men in the general population . . . and even higher compared to women.” Leading causes of death included heart disease, cancer, and suicide. An earlier study found a 51 percent higher mortality rate in trans-identifying males than the general population. Notably, current estrogen use, rather than past use, was linked to these increased risks, suggesting long-term exposure to feminizing hormones may amplify health risks over time.

Beyond these headline findings, the paper outlines several additional risks. Autoimmune diseases such as lupus and systemic sclerosis have occasionally appeared or worsened following the initiation of estrogen therapy. One patient with a skin-limited autoimmune condition developed life-threatening kidney complications after starting hormones. At the population level, males with gender identity disorders have been found to have a more than sixfold increased risk of developing multiple sclerosis—raising the possibility that estrogen may act as a trigger for autoimmune responses in some individuals.

Estrogen also appears to affect metabolism. Hormone therapy has been associated with increased fat mass, muscle loss, and reduced insulin sensitivity—an early warning sign for diabetes. In one study, insulin resistance rose by more than 80 percent over two years of use. Elevated triglycerides—a type of fat in the blood—have been linked to serious complications in trans-identifying males, including pancreatitis and gallstones.

The authors also review cancer risks. Trans-identifying males on estrogen are significantly more likely to develop breast cancer than non-trans-identifying men. One cited analysis estimated the risk to be 22 to 40 times higher. While breast cancer remains rare in men overall, such increases are noteworthy.

The paper also highlights elevated rates of thyroid and testicular cancers among trans-identifying males on estrogen. Some studies suggest a potential link between testicular cancer and long-term use of estrogen or testosterone blockers. Public drug safety databases in the U.S. and France reflect similar concerns, listing tumors, cardiovascular complications, and brain tumors—such as meningiomas—among the most frequently reported adverse events.

One especially unsettling section explores how estrogen may affect the male brain. A few small brain-imaging studies found that several months of estrogen use led to “an increase in ventricular volume and a decrease in brain volume.” Studies in male rats showed similar effects: estrogen and testosterone blockers reduced brain volume and altered brain chemistry. The authors suggest these changes may result from disruptions in how water is regulated in brain cells—potentially mimicking patterns seen in degenerative diseases.

The paper also notes that levels of BDNF—a brain chemical critical for mood and memory—tend to decline in patients on cross-sex hormones. Low BDNF is associated with depression and shrinkage of the hippocampus, a brain region essential for memory. Taken together, these findings raise the possibility that estrogen may produce lasting changes in male brain structure and function.

In the paper’s final section, the authors stress that even if some of these harms are based on limited evidence, they should still be taken seriously. “[M]edical decision-making tends to prioritize avoiding harm over achieving benefit,” the authors observe, “particularly when harms are severe and benefits are modest.” Many of the risks discussed here are life-altering or life-threatening, while randomized controlled trials showing long-term benefits of estrogen for this population are nonexistent. Some advocates argue that these treatments prevent suicide, but a recent major study found “no psychosocial improvement among natal males.” Earlier studies making stronger claims have since been corrected or discredited due to flawed methods.

The new paper’s authors call for more rigorous long-term research, especially studies that separate hormone effects from other factors like mental illness or previous treatments. They note that many systematic reviews gloss over side effects, and that some major safety reports commissioned by activist medical organizations like WPATH remain unpublished. Countries with national health databases—like Sweden and the Netherlands—could provide valuable longitudinal data for researchers willing to investigate these questions with scientific integrity.

Of course, the study has limitations. It’s not a formal systematic review, but rather a comprehensive summary of published evidence. Much of the data come from observational studies or case reports, which can’t prove cause and effect. But that’s true of most research in this field, as high-quality long-term trials don’t yet exist.

The value of this paper lies in its wide-angle view of risks that activist and medical circles have too often downplayed or ignored. While the findings don’t amount to conclusive proof of harm in every case, they make a compelling case for caution, transparency, and scientific integrity—qualities frequently missing in the rush to medicalize gender distress.

That this kind of research is only now being done—after thousands of teens have already started irreversible treatments—is troubling. That many of the safety signals are only now becoming detectable—because so many people have recently been exposed to these interventions—should be a sobering wake-up call.

Still, we have reason for hope. The voices of concerned clinicians, detransitioners, and independent scientists are becoming harder to dismiss. The public is asking tougher questions, and the medical establishment is beginning to confront the real costs of its rush to affirm identity over evidence. A better, safer, and more ethical path remains possible if we’re willing to follow the facts where they lead.

--

Abstract

Efforts to alleviate the psychological distress of gender dysphoria have included the use of exogenous estrogen (often with anti-androgens) to alter secondary sex characteristics of natal males. In response to the rapid increase in presenting cases among young people, extensive scrutiny has now been brought to bear on these medical interventions for minors, with ESCAP reporting “an urgent need for safeguarding clinical, scientific, and ethical standards.” However, due to the lack of systematic outcome data, the associated risk–benefit profile is unknown. Several recent systematic reviews have found the evidence of benefit to be of low or very low certainty, while some risks, such as infertility, have been long recognized. This paper compiles several emerging and accumulating safety signals in the medical literature. These range from increased rates of previously associated adverse outcomes with long-term estrogen use (e.g., acute cardiovascular events) to associations of estrogen use with newly identified adverse outcomes. Estrogen also induces changes in the brain, raising concerns for negative impacts on mood (e.g., depression) and cognition. These safety signals indicate the need for further investigation and a thorough systematic search for others, which may now be more evident due to the increased number of young people receiving these treatments. There is an urgent need for the evidence base to be improved with more studies, especially those with systematic long-term follow-up and those that can disentangle possible confounders, as well as systematic reviews to help interpret their reliability.

==

[kaybrony]

What MII-58 could realistically be made of ( based on my very odd analysis of the diaries + memories )

MII-58 seems to contain high levels of vasopressin and oxytocin ( two closely related hormones that mess with the behavior of one influenced by it ) , one also being known as " the love hormone " , which causes one to be protective of another in a way that also makes one jealous easily .

A drug that includes these hormones is sertraline , which is mainly used as an antidepressant . ( In the diary , we see MII-58 be used as one by Moka's father after she attempts suicide for the first time . )

In the game we see increase of hostility and aggression after taking MII-58 , which also happens when someone uses a methylphenidate transdermal patch . Methylphenidate is commonly used an ADHD medication and to increase focus in someone . ( Something that Moka's father wanted her to do instead of spending time in the sewing club with Alan . )

To further prove that these could be likely factors in MII-58 , both can be safely mixed together but also have occasional side effects . One that particularly caught my eye was hallucinations being found when taking both drugs together . ( If you go onto the old website , you'll see Alan's logs that take place during WE0 . In it he mentions hearing Moka whisper something under her breath , almost as if she was talking to someone else , which we can infer as an auditorial hallucination of hers or possibly even NULL guiding her words . )

@i-love-moka <- wakey wakey eggs and bakey

[circumlocutive]

Having a midday WFH wank and I got distracted because one of the actors had a patch on their skin and I was like oh is that a nicotine patch or one of the newer transdermal patches they're doing for drug delivery these days? And started thinking about microneedle patch fabrication techniques and my bioengineering design final (continuous drug delivery via patch and pump, inspired by diabetic patch pump systems, using a constant flow rate to avoid side effects from the bolus effect)

And well now I'm just thinking about pharmacokinetics

[tamasin]

Post D-3 H-22 335940-0 11.04.2834

ATTN: D-3 Requisitions Subject: Restock

Barndog - Restock isn't too intense this time, the newer dogs have better trigger discipline than the older ones. See notes below.

Barndog - Special note on line 10. Any product not adhering to the request will be rejected. If you can't find enough in your stock reach out to K899 in R&D, they have some earmarked for us.

Vanity - Gentle reminder that a K behind a number signifies thousands. Don't haze the new guy who messed that one up too badly. They packed up the box of 45 25mm shells very neatly and professionally.

Vanity - We've been getting reports of a high rate of dud caseless charges. We'll be overloading the feeds to compensate. Note increased order quantity on line item 5.

Hangar 22 is requesting the following:

Ammunition

25mm CL-HEI: 45k

25mm CL-AP-T: 10k

25mm CL-AP: 44,955 units.

25mm CL-SAPHEI: 20k

25mm CL-Charges: 150k

70 k-grain DI: 300

35 k-grain DI-F: 10k

10 k-grain DI: 204k

10 k-grain 6 charge sabots: 34k

Stims/Meds.

30k units: AD-V900, production date pre-00.02.2834

80k units: CI-E60, any production date.

3 tanks: P-803 sterile flush

450 units Spironolactone 100mg

300 units Estradiol Sublingual tablets 2mg

50 units Estradiol Transdermal Patches 0.1mg

90 units Testosterone Cypionate

10k units Vitamin D3 20,000 IU

90 units Synthroid 0.05mg

800 units Primary Vitamin Blend KVA

Misc

5 pcs: 008-6653: 30mm hose, 30 meters long, type G couplings.

1 pc: 183-9433: Welding whip, 5 meters. Type A connector

3 pcs: 183-9401: Welding gun. Type A connector.

Thanks, as usual. - Barndog.

Maintenance Crew, Dock 3, Hangar 22

First Maintenance Posting

Previous Maintenance Posting

Next Maintenance Posting

[felixcloud6288]

Metaphor Re:Fantazio 7/11

Today, Darin is going to the Abandoned Tomb. It's a two-day trip to reach there.

For the afternoon activity along the way, Darin helped Strohl sharpen weapons. Then the party was attacked by a rival candidate.

Goddard is weak to lightning attacks. He can attack twice per turn and has a move that lowers the party's hit/evade. So the best approach is to hit hard and fast. But otherwise, he's not a tricky opponent.

You can steal a Polarity Magnet from him. It's an accessory that prevents paralysis.

Beating Goddard unlocks him Memorandum entry. He used to work in demolition to rebuild Montario after it was annexed, but he was replaced by younger workers. He thinks the young are trying to push out the old, but if this world is anything like ours, he got replaced because the company he worked for didn't want to pay him what he's worth and decided to hire young, inexperienced workers they could more easily exploit. If Goddard wants to focus his anger toward the correct target, he should join Catherina's campaign to guillotine the rich.

There are three things about Goddard's design that got my interest.

First, He wears a dog-tag, so he might be a veteran soldier during the Annex War. I don't know how long ago that was, but he was alive during it.

Second, his tribal tattoos are designed to make it look like he has a scar going down the left side of his head. Despite being alive during the Annex War, he probably never actually fought in it. And he arranged his tattoo to look like a battle wound.

Finally, there's a green patch on his neck. It might be a dermal or transdermal medical patch of some kind.

Overall, He's someone who's lived through hard times and is struggling due to lack of work opportunities and medical complications due to old age. His pension idea is a good idea that can be added on top of Darin's general "help those in need" policies.

That night, Darin played board games with Hulkenberg.

Darrin's party reached the Ancient Tomb that afternoon. Before reaching it, he and Strohl did more weapon maintenance. Strohl talked about the various types of swords and their cutting power. However, the most dangerous sword is a dull one because it might fail you when you need it most.

To maximize MAG from that discussion, you need to tell Strohl any weapon can be dangerous.

Once Darrin reached the Abandoned Tomb, he got the Malveno's Ring at returned to Martira.

Timi slept all day.

Darin is level 25 and ranked 2711st. Darrin is level 29 and ranked 381st. Timi is level 23 and ranked 3788th.

This day is a little short so I guess I'll talk about something I've had in my pocket for a little while.

Whenever you get an opportunity to roll back your save file to an earlier day, like when you miss a deadline, everything is rolled back to what it was at the start of that day.

It made me think a little bit about how the data in a save file is organized.

Presumably, the save is in a JSON-esque file that contains fields for player name, party levels, Archetype levels, experience, item counts, etc. But then there is a sub-section for a rollback save file as well.

The game autosaves at the beginning of each day. When you reach certain days like 6/17, the game has to make a secret rollback save that gets added to the save file after.

I've been rotating save files across the 16 slots you're given in case a recording fails or I accidentally overwrite the wrong file. At the moment, the saves are using a total of 138 MB.

Just for a quick comparison, I started up a clean version of the game with no save data and the system save data took up 3.15 MB and the first autosave after getting control of the protagonist increased the save data to 11.08 MB. Then when I was able to make a manual save, it increased to 19.01 MB. Then I realized where the math on all this was going and I saved to all 16 slots to confirm that 16 brand new save files + 1 fresh autosave take up 138 MB.

So with this information, I have discovered that a Metaphor save file is roughly 7.93 MB and starts with every single datapoint that might be relevant. The save file starts with fields for every Archetype in the game regardless of if you have access to it, every item in the game regardless of if you are carrying one with you, and every treasure or pickup regardless of if you can get to it.

Since items are not unique, there's a finite number of item IDs the game would need to account for. And field item IDs and treasure chest IDs can be reduced to a simple boolean for whether or not the player grabbed it. So there is a finite cap to how big a save file in Metaphor will grow and the developers decided to just front-load every field into the save from the start rather than add fields as needed. And the save would need to make two copies of almost every field so the player can roll their save back to a previous day.

back

[freedom-barricades-bighero16]

Moving into the CoM part 3 mutant designs today. I knew that the crew would've thought about Di mutating herself as a last resort...

Basically her form is that of a grey wolf + widow spider, although her face in the final design kinda looks like a fox. Not that I mind though, it looks less repetitive anyway.

In the final story Di had chipped herself, but this is drawn before I made that change, and she used a transdermal patch just like the original script.

[mastergarryblogs]

Diabetes Devices Market Growth: The Hidden Forces Driving Demand

Diabetes Devices Market Overview: Precision Tools Driving a Diabetes Care Revolution

The global diabetes devices market is undergoing a profound transformation, fueled by groundbreaking innovations in glucose monitoring, insulin delivery systems, and integrated management platforms. From 2024 to 2031, the diabetes devices market is projected to expand at a robust CAGR of 7.45%, reflecting rising diabetes prevalence, technological progress, and a paradigm shift toward patient-centered chronic disease management.

Diabetes technologies are no longer limited to mere tools for blood sugar testing—they have evolved into intelligent systems that enhance real-time decision-making and clinical outcomes.

Request Sample Report PDF (including TOC, Graphs & Tables): https://www.statsandresearch.com/request-sample/40486-global-diabetes-devices-market

Advanced Blood Glucose Monitoring Devices: Real-Time Insights for Optimal Control

Self-Monitoring Blood Glucose (SMBG)

SMBG devices remain foundational for day-to-day blood glucose management. These compact, portable glucometers empower patients with immediate feedback, helping them fine-tune lifestyle and medication adherence.

Key benefits:

Instant readings from small blood samples

Increased patient autonomy

Portability for routine and emergency checks

Continuous Glucose Monitoring (CGM) Systems

CGMs deliver continuous, real-time glucose readings and trend data. Equipped with sensors, transmitters, and receivers, CGMs reduce the need for fingersticks and provide predictive alerts for hypo- or hyperglycemia.

Key CGM advancements:

14+ day sensor wear

Bluetooth-enabled smartphone synchronization

AI-based analytics for glucose forecasting

HbA1c Testing Devices

HbA1c kits quantify average glucose control over 2–3 months:

Point-of-care devices for rapid, on-site diagnostics

Laboratory systems for comprehensive accuracy

HbA1c remains a clinical gold standard for evaluating therapy efficacy and long-term risk mitigation.

Get up to 30%-40% Discount: https://www.statsandresearch.com/check-discount/40486-global-diabetes-devices-market

Intelligent Insulin Delivery Systems: Automation Meets Accuracy

Insulin Pens

Favored for their precision and ease of use, insulin pens now feature:

Dose memory logs

App connectivity

Pre-filled cartridges to reduce waste

Insulin Pumps

Pumps offer continuous subcutaneous insulin infusion (CSII) and can be fine-tuned based on CGM data:

Basal-bolus automation

Meal-time dosing adjustments

Wearable, discreet form factors

Jet Injectors and Syringes

Jet injectors provide needle-free delivery via high-pressure microstreams, enhancing comfort and compliance. Conventional syringes, although less technologically advanced, remain cost-effective and widely used in certain demographics.

Artificial Pancreas Systems: The Apex of Closed-Loop Innovation

Artificial pancreas systems represent a pinnacle in diabetes tech, seamlessly integrating CGM data with insulin pumps to deliver fully automated insulin dosing. These systems minimize glycemic variability and improve time-in-range metrics.

Key Features:

Real-time glucose sensing

Algorithm-driven insulin titration

Auto-correction boluses

They herald a future of "hands-off" diabetes management, dramatically reducing patient burden.

Technology-Based Segmentation: The Age of Wearables, Non-Invasive, and Implantable Solutions

Wearable Devices

Wearables dominate the CGM and pump sectors. These smart devices improve user experience by integrating with:

Mobile apps

Smartwatches

Cloud-based physician dashboards

Non-Invasive Technologies

Emerging innovations eliminate blood draws, using:

Sweat, interstitial fluid, or optical signals for glucose detection

Painless insulin administration via transdermal patches or microneedles

Implantables

Implantable sensors, like Eversense, offer 180-day wear periods and minimal maintenance. Future prospects include fully implantable insulin pumps, aiming to redefine long-term diabetes care.

Strategic Distribution Channels: Multi-Access Approaches to Device Availability

Hospital Pharmacies

Institutional procurement hubs providing inpatient access to:

Advanced CGMs

Emergency-use insulin delivery systems

Diagnostic kits

Retail Pharmacies

Community-focused outlets that offer:

Immediate patient counseling

High-availability insulin pens and meters

Support for device onboarding

Online Pharmacies

Digital-first platforms providing:

Subscription-based sensor replacements

Remote device calibration

Rapid delivery of critical supplies

Diabetes Clinics and Home Care

Specialized care centers and in-home setups enable:

Personalized device configurations

Telehealth integration

Longitudinal glucose trend analysis for home-managed patients

Regional Diabetes Devices Market Insights: Diverse Demand Across Geographies

North America

U.S. leads the global market with deep penetration of CGMs and artificial pancreas systems

Strong presence of key players such as Dexcom, Medtronic, Insulet

Europe

High adoption of insulin pumps in Germany, UK, and France

Expanding reimbursement frameworks fostering CGM use

Asia-Pacific

Explosive growth in China, India, Japan, driven by rising diabetes incidence

Government subsidies and healthtech startups catalyze device access

Middle East, Africa, and South America

Improving healthcare infrastructure

Strategic partnerships with global manufacturers expanding regional footprints

Leading Companies Transforming the Diabetes Devices Market

Medtronic plc – Leader in closed-loop insulin delivery systems

Dexcom Inc. – Pioneer in CGM technology and real-time data integration

Abbott Laboratories – Innovator of sensor-based FreeStyle Libre systems

Insulet Corporation – Renowned for tubeless insulin pump design (Omnipod)

Novo Nordisk A/S – Dominant in insulin pens and injectors

Ypsomed Holding – Developer of user-friendly pen platforms and mobile apps

Arkray Inc. – Key manufacturer of SMBG devices for emerging markets

Projected Growth: 2024–2031 Forecast

The global diabetes devices market is projected to surpass prior milestones, reaching substantial valuation by 2031. Growth is underpinned by:

Technological breakthroughs in non-invasive monitoring

Rising global awareness and screening programs

Increasing demand for real-time digital health solutions

Purchase Exclusive Report: https://www.statsandresearch.com/enquire-before/40486-global-diabetes-devices-market

Conclusion

The global diabetes devices market is advancing toward a future where data-driven automation, patient empowerment, and seamless integration define chronic disease management. As demand escalates across regions and demographics, companies that prioritize innovation, usability, and personalization will lead the next chapter in diabetic care. With sophisticated tools becoming more accessible and user-friendly, we are witnessing a technological renaissance poised to transform the lives of millions worldwide.

Our Services:

On-Demand Reports: https://www.statsandresearch.com/on-demand-reports

Subscription Plans: https://www.statsandresearch.com/subscription-plans

Consulting Services: https://www.statsandresearch.com/consulting-services

ESG Solutions: https://www.statsandresearch.com/esg-solutions

Contact Us:

Stats and Research

Email: sales@statsandresearch.com

Phone: +91 8530698844

Website: https://www.statsandresearch.com

[sheasapothecary]

Tips for using pain relief patches

Pain relief patches are also called transdermal patches, and these patches are a type of medication that can be used to treat pain and other conditions. 

Tips for using pain relief patches:

Clean the area where you have to apply the patch.

Ensure to apply the patch to non-hairy skin. 

When it's time to remove the patch, place the new patch on a different area of skin. 

Avoid applying a heating pad on the patch.

Talk to your healthcare provider before using a pain relief patch.

[r1ch-ln4mst3r]

why am i nervous to use my 3mg transdermal thc patch? why am i trying to schedule it like it's an acid trip lol

[sanjivananusandhan]

Contract Pharmaceutical Manufacturing: Complete Industry Analysis

Overview of Contract Pharmaceutical Manufacturing

Contract pharmaceutical manufacturing represents a fundamental shift in how pharmaceutical companies approach production and distribution. This business model enables pharmaceutical companies to outsource their manufacturing operations to specialized contract manufacturing organizations (CMOs), allowing them to focus on core competencies such as research, development, and marketing. Many pharma companies in Sonipat have embraced this model, providing reliable, high-quality manufacturing solutions that support both domestic and international pharmaceutical brands.

The global contract manufacturing industry has experienced unprecedented growth, driven by increasing demand for pharmaceutical products, cost pressures, and the need for specialized manufacturing expertise. This growth has transformed the pharmaceutical supply chain, creating new opportunities for both pharmaceutical companies and contract manufacturers.

Evolution and Market Dynamics

Historical Development

The contract manufacturing model emerged as pharmaceutical companies sought to optimize their operations and reduce capital expenditures. Initially focused on basic manufacturing services, the industry has evolved to offer comprehensive solutions including formulation development, regulatory support, and supply chain management.

Current Market Landscape

Today's contract manufacturing market encompasses a diverse range of services and capabilities. From small-scale specialty manufacturers to large multinational organizations, contract manufacturers serve pharmaceutical companies of all sizes across various therapeutic areas and geographic markets.

Growth Drivers and Trends

Several factors continue to drive growth in the contract manufacturing sector. Patent expirations create opportunities for generic drug manufacturing, while increasing regulatory complexity drives demand for specialized compliance expertise. Additionally, emerging markets present new opportunities for cost-effective manufacturing solutions.

Types of Contract Manufacturing Services

Primary Manufacturing

Primary manufacturing involves the production of active pharmaceutical ingredients (APIs) and bulk drug substances. This critical step in pharmaceutical production requires specialized facilities, equipment, and expertise to ensure product quality and regulatory compliance.

Secondary Manufacturing

Secondary manufacturing encompasses the formulation and packaging of finished pharmaceutical products. This includes tablet compression, capsule filling, liquid formulation, and various packaging operations that prepare products for distribution and sale.

Specialized Manufacturing Services

Advanced contract manufacturers offer specialized services including sterile manufacturing, controlled substance handling, cold chain management, and complex drug delivery systems. These specialized capabilities enable pharmaceutical companies to access expertise that would be costly to develop internally.

Manufacturing Technologies and Capabilities

Solid Dosage Manufacturing

Solid dosage manufacturing represents the largest segment of contract manufacturing services. This includes tablet compression, capsule filling, and coating operations using advanced equipment and process controls to ensure consistent product quality.

Liquid and Injectable Products

Liquid formulation and injectable product manufacturing require specialized facilities with stringent environmental controls. These operations demand expertise in sterile manufacturing, contamination control, and specialized packaging systems.

Advanced Drug Delivery Systems

Modern contract manufacturers increasingly offer capabilities for complex drug delivery systems including sustained-release formulations, transdermal patches, inhalation products, and targeted delivery mechanisms. These advanced capabilities support pharmaceutical innovation and product differentiation.

Quality Management and Regulatory Compliance

Good Manufacturing Practices

Contract manufacturers must adhere to comprehensive Good Manufacturing Practices (GMP) that govern all aspects of pharmaceutical production. These practices ensure product quality, safety, and efficacy while meeting regulatory requirements across multiple jurisdictions.

International Regulatory Standards

Leading contract manufacturers maintain compliance with various international regulatory standards including FDA regulations, European Medicines Agency (EMA) guidelines, WHO-GMP standards, and country-specific regulatory requirements. This multi-jurisdictional compliance enables global market access.

Quality Systems and Controls

Robust quality management systems encompass raw material testing, in-process controls, finished product testing, and comprehensive documentation systems. These quality controls ensure consistent product quality and facilitate regulatory inspections and audits.

Supply Chain Management and Logistics

Raw Material Sourcing

Effective supply chain management begins with reliable sourcing of raw materials, APIs, and packaging components. Contract manufacturers develop supplier networks that ensure material quality, availability, and cost-effectiveness while maintaining regulatory compliance.

Inventory Management

Sophisticated inventory management systems optimize material flow, minimize waste, and ensure product availability. These systems integrate with production planning and customer demand forecasting to maintain efficient operations.

Distribution and Logistics

Contract manufacturers often provide integrated logistics services including warehousing, distribution, and cold chain management. These services ensure product integrity throughout the supply chain while reducing costs and complexity for pharmaceutical companies.

Technology Integration and Innovation

Process Automation

Modern contract manufacturing facilities incorporate advanced automation technologies that improve efficiency, reduce human error, and enhance product consistency. Automated systems span from raw material handling to finished product packaging and labeling.

Data Management and Analytics

Comprehensive data management systems capture and analyze manufacturing data to optimize processes, predict maintenance needs, and ensure regulatory compliance. Advanced analytics support continuous improvement initiatives and quality enhancement programs.

Digital Manufacturing Technologies

Emerging digital technologies including artificial intelligence, machine learning, and Internet of Things (IoT) applications are transforming pharmaceutical manufacturing. These technologies enable predictive maintenance, real-time quality monitoring, and optimized production scheduling.

Economic Benefits and Cost Considerations

Capital Investment Optimization

Contract manufacturing enables pharmaceutical companies to avoid significant capital investments in manufacturing infrastructure, equipment, and facilities. This capital optimization allows companies to focus resources on research, development, and market expansion activities.

Operational Cost Reduction

Outsourcing manufacturing operations can reduce overall production costs through economies of scale, operational efficiency, and specialized expertise. Contract manufacturers leverage their scale and specialization to provide cost-effective manufacturing solutions.

Risk Mitigation

Contract manufacturing helps pharmaceutical companies mitigate various risks including regulatory compliance, technology obsolescence, and capacity management. Experienced contract manufacturers provide expertise and infrastructure that reduce operational risks.

Global Market Trends and Opportunities

Emerging Market Expansion

Growing pharmaceutical markets in Asia, Africa, and Latin America present significant opportunities for contract manufacturing expansion. These markets offer cost advantages, skilled workforces, and increasing regulatory sophistication.

Biosimilar Manufacturing

The growing biosimilar market creates new opportunities for specialized contract manufacturers with biological manufacturing capabilities. This segment requires sophisticated facilities, specialized expertise, and comprehensive regulatory knowledge.

Personalized Medicine Manufacturing

Advances in personalized medicine and precision therapeutics create opportunities for specialized manufacturing services. These applications often require flexible manufacturing capabilities and small-batch production expertise.

Challenges and Risk Management

Regulatory Complexity

Navigating complex and evolving regulatory requirements across multiple jurisdictions presents ongoing challenges for contract manufacturers. Maintaining compliance requires continuous investment in regulatory expertise and quality systems.

Supply Chain Disruptions

Global supply chain disruptions can impact raw material availability, production schedules, and customer deliveries. Contract manufacturers must develop resilient supply chains and contingency planning to manage these risks.

Intellectual Property Protection

Protecting customer intellectual property and maintaining confidentiality requires robust security measures and comprehensive legal frameworks. Contract manufacturers must demonstrate their ability to safeguard sensitive information and proprietary technologies.

Strategic Partnerships and Collaboration Models

Long-term Strategic Partnerships

Many pharmaceutical companies are moving beyond transactional relationships to develop long-term strategic partnerships with contract manufacturers. These partnerships often include joint investment in capabilities, shared risk and reward structures, and collaborative development programs.

Technology Transfer and Development

Effective technology transfer processes ensure successful transition of pharmaceutical products from development to commercial manufacturing. This requires close collaboration between pharmaceutical companies and contract manufacturers throughout the development and scale-up process.

Integrated Service Models

Comprehensive service models that integrate manufacturing with additional services such as regulatory support, supply chain management, and market access support provide added value to pharmaceutical companies while strengthening partnership relationships.

Future Outlook and Industry Evolution

he contract pharmaceutical manufacturing industry continues to evolve in response to changing market dynamics, technological advances, and regulatory requirements. Future growth will be driven by increasing demand for pharmaceutical products, continued cost pressures, and the need for specialized manufacturing capabilities. Pharma companies in Sonipat are well-positioned to capitalize on these trends, offering advanced infrastructure, skilled expertise, and flexible production capacity to meet the industry's growing needs.

Innovation and Technology Adoption

Continued adoption of advanced manufacturing technologies, digitalization, and innovative production methods will enhance efficiency, quality, and flexibility in contract manufacturing operations. These technological advances will enable new service offerings and improved customer value.

Market Consolidation and Expansion

The industry is likely to experience continued consolidation as larger contract manufacturers acquire specialized capabilities and expand their geographic reach. This consolidation will create more comprehensive service providers while maintaining competitive market dynamics.

Conclusion

Contract pharmaceutical manufacturing has become an integral component of the global pharmaceutical industry, providing essential services that enable pharmaceutical companies to bring life-saving medications to market efficiently and cost-effectively. The industry's continued evolution reflects its importance in supporting pharmaceutical innovation and meeting growing global healthcare needs.

The success of contract manufacturing partnerships depends on careful selection of manufacturing partners, effective collaboration throughout the product lifecycle, and shared commitment to quality, compliance, and continuous improvement. As the pharmaceutical industry continues to evolve, contract manufacturing will play an increasingly important role in supporting innovation, improving access to medicines, and delivering value to patients worldwide.

[visionhealthandcare]

What’s changing in the way medicines are delivered to the body?

Gone are the days when taking a pill or getting a shot were the only ways to treat disease. A silent revolution is happening in healthcare, powered by new technologies that are making drug delivery more targeted, efficient, and personalized than ever before. From nano-carriers that navigate the bloodstream like GPS-guided drones, to implants that release medications over months, innovation in this space is transforming how—and how well—patients receive treatment.

These game-changing innovations are fueling massive interest in the Advanced Drug Delivery Market, where pharmaceutical companies, biotech firms, and healthcare providers are racing to develop smarter, safer, and more effective ways to deliver medication.

Why does drug delivery matter so much in modern medicine?

The success of any medication isn’t just about what’s in it—but how it reaches the right part of the body at the right time. Poor absorption, side effects, and patient non-compliance have long been problems in traditional drug administration. Advanced delivery systems solve this by improving bioavailability, minimizing waste, and allowing for controlled release.

In short, better delivery equals better outcomes. That’s why diseases like cancer, diabetes, asthma, and neurological disorders are all benefiting from next-gen drug delivery technologies.

What types of innovations are leading the way?

Some of the most exciting advancements include:

Nanoparticles and liposomes that deliver drugs directly to diseased cells while sparing healthy tissue

Transdermal patches that provide continuous drug flow without needles

Implantable pumps and microchips that release medication over months or even years

Oral thin films and microneedles offering painless alternatives to injections

These solutions don’t just improve effectiveness—they also drastically improve the patient experience. Fewer side effects and less frequent dosing means people are more likely to stick with their treatment plans.

How does this shift align with trends in other healthcare segments?

This personalized, precision-driven approach is also evident in sectors like the GCC Dental Anesthesia Market, where patient-centric innovations are shaping safer, more efficient anesthesia delivery. The UK Dental Anesthesia Market similarly shows how localized, targeted care leads to better patient experiences and outcomes.

Across the board, healthcare is moving toward systems that deliver the right treatment at the right moment, using the least invasive methods possible. Advanced drug delivery is a natural extension of that shift.

What challenges still face this market?

Despite the progress, adoption is not without obstacles. These technologies often come with higher development and manufacturing costs, and regulatory approvals can be more complex due to novel mechanisms of action. There’s also the challenge of clinician and patient education—introducing entirely new methods of treatment requires building trust and understanding.

However, as the benefits become clearer—especially in chronic disease management and cancer therapy—healthcare systems are beginning to embrace these options as long-term cost-saving and life-saving solutions.

What does the future of drug delivery look like?

Imagine a future where your medication knows exactly when and where it’s needed. You might wear a patch that automatically adjusts your insulin levels. Or receive a cancer drug wrapped in a smart nanoparticle that bypasses healthy tissue completely. Or take a pill embedded with a sensor that tells your doctor if you’ve taken your dose.

This isn’t science fiction—it’s already happening. And the Advanced Drug Delivery Market is rapidly becoming the epicenter of this transformation. With ongoing innovation, supportive policy shifts, and rising demand for more effective care, this market is not just expanding—it’s redefining the very concept of treatment.

In the race for smarter, more personalized healthcare, how we deliver drugs could be just as important as what’s in them.

[sheasapothecary]

Vitamin Patches: The Potential Health Benefits

A Vitamin patch can deliver essential amounts of vitamins and nutrients. Using these transdermal patches can offer several health benefits. These may include.